ICON (NASDAQ:ICLR), a global provider of outsourced
development services to the pharmaceutical, biotechnology and medical
device industries, today announced that it now expects its Central Lab
business unit to return to profit in the second quarter ending June
30th, a quarter earlier than recently guided.
"We are very pleased that strong revenue growth in the lab,
supported by excellent new business wins, has accelerated our return
to profitability in this unit. Our core clinical business continues to
perform in line with plans" said CEO Mr. Peter Gray.
About ICON
ICON is a global provider of development services to the
pharmaceutical, biotechnology and medical device industries,
specializing in the management, execution and analysis of complex,
multinational clinical trials. ICON teams have successfully conducted
over 1900 development projects and over 2300 consultancy engagements
across all major therapeutic areas. ICON currently has over 3400
employees, operating from 42 offices in 28 countries.
Further information is available at www.iconclinical.com.
